Company Encyclopedia
View More
name
Skye Bioscience
SKYE.US
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc.
1.945 T
SKYE.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pomerantz LLP Moves to File Class Action Against Skye Bioscience, Inc. – SKYE

    Pomerantz LLP has filed a class action lawsuit against Skye Bioscience, Inc. and certain officers, alleging violations of federal securities laws. The lawsuit, filed in the Southern District of California, claims Skye made false statements about its drug nimacimab's efficacy. Following disappointing trial results, Skye's stock fell 60%. Investors have until January 16, 2026, to seek lead plaintiff status. The lawsuit seeks damages for those who acquired Skye securities between November 4, 2024, and October 3, 2025.

    Acceswire·
    US
    SKYE
    -1.84%
    Acceswire·
    US
    SKYE
    -1.84%

    15:17 ET SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

    Rosen Law Firm reminds investors of Skye Bioscience, Inc. (NASDAQ: SKYE) securities fraud lawsuit for those who purchased between November 4, 2024, and October 3, 2025. The lead plaintiff deadline is January 16, 2026. Investors may be entitled to compensation. The lawsuit alleges false and misleading statements about Skye's business and prospects. Contact Rosen Law Firm for more information.

    prnewswire·
    US
    SKYE
    -1.84%
    prnewswire·
    US
    SKYE
    -1.84%

    Pomerantz LLP Moves Forward with Class Action Litigation Against Skye Bioscience, Inc. – SKYE

    Pomerantz LLP has filed a class action lawsuit against Skye Bioscience, Inc. and certain officers, alleging false and misleading statements about the efficacy of their product nimacimab. The lawsuit seeks damages for investors who acquired Skye securities between November 4, 2024, and October 3, 2025. Skye's stock fell 60% after announcing that nimacimab did not meet its primary endpoint in a clinical trial. Investors have until January 16, 2026, to seek appointment as Lead Plaintiff.

    Acceswire·
    US
    SKYE
    -1.84%
    Acceswire·
    US
    SKYE
    -1.84%

    Skye Bioscience Signs Collaboration and License Agreement with Halozyme

    Skye Bioscience Inc. has signed a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. for the use of Halozyme’s ENHANZE® drug delivery technology. The agreement includes milestone and royalty payments, with Halozyme supplying clinical and commercial rHuPH20 bulk drug product. This collaboration aims to develop a subcutaneous formulation of nimacimab.

    Reuters·
    US
    SKYE
    -1.84%
    US
    HALO
    +0.07%
    Reuters·
    US
    SKYE
    -1.84%
    US
    HALO
    +0.07%

    Investors File Class Action Lawsuit Against Skye Bioscience Inc

    A class action lawsuit has been filed against Skye Bioscience Inc. for alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025. The law firm Levi & Korsinsky is handling the case, encouraging affected investors to explore their rights and recovery options. The original content was published by Skye Bioscience Inc. via ACCESS Newswire.

    Reuters·
    US
    SKYE
    -1.84%
    Reuters·
    US
    SKYE
    -1.84%
    © 2025 Longbridge｜Disclaimer